Towards a new therapy in psoriasis and psoriatic arthritis
Inhibitec Anticuerpos S.L. has been selected as a recipient of the grant CPP2022-009666, supporting the development of the public–private collaborative project “Towards a new therapy in psoriasis and psoriatic arthritis”, within the framework of the Plan Estatal de Investigación Científica, Técnica y de Innovación (PEICTI) 2021–2023.
Grant CPP2022-009666 funded by MICIU/AEI/ 10.13039/501100011033 and by the “European Union NextGenerationEU/PRTR.
The objective of the project is to advance new therapeutic approaches for psoriasis and psoriatic arthritis through collaboration between public research institutions and private partners. With a total budget approved of 781,080€, it has been running from 01/12/2023 to 30/11/2026.
This initiative is led by Victoria Casado-Medrano (Project Coordinator and PI at Inhibitec), Ramon Merino (PI at CSIC), Marcos López Hoyos (PI at IDIVAL), Mar García Sáiz (PI at SCReN and IDIVAL), and Daniel Heinisch (AI Research, Recog Analytics).
